Oscotec Inc. (KOSDAQ:039200)

Market Cap	1.49T +28.3%
Revenue (ttm)	99.84B +193.6%
Net Income	52.34B +5,871.6%
EPS	1,368.00 +5,868.9%
Shares Out	38.26M
PE Ratio	28.55
Forward PE	46.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	148,546
Average Volume	260,258
Open	40,000
Previous Close	38,850
Day's Range	38,600 - 41,150
52-Week Range	25,850 - 66,000
Beta	n/a
RSI	29.39
Earnings Date	May 26, 2026

About Oscotec

Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1998
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 039200

Financial Performance

In 2025, Oscotec's revenue was 99.84 billion, an increase of 193.58% compared to the previous year's 34.01 billion. Earnings were 52.34 billion, an increase of 5871.65%.